Sanjay K Murthy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2456156/publications.pdf

Version: 2024-02-01

535685 466096 1,201 46 17 32 h-index g-index citations papers 49 49 49 1558 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. Digestive Diseases and Sciences, 2022, 67, 2471-2479.	1.1	9
2	Association Between Endoscopist Specialty and Colonoscopy Quality: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 1931-1946.	2.4	12
3	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 2607-2618.e14.	2.4	13
4	Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study. Journal of the Canadian Association of Gastroenterology, 2021, 4, e16-e30.	0.1	10
5	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Lamp; Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.1	2
6	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. Journal of the Canadian Association of Gastroenterology, 2021, 4, S34-S39.	0.1	2
7	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S20-S26.	0.1	0
8	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S40-S45.	0.1	4
9	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.1	7
10	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.1	5
11	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S27-S33.	0.1	3
12	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.1	9
13	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. American Journal of Gastroenterology, 2021, 116, 1284-1293.	0.2	12
14	Shifting Health Care Use from Hospitalisations and Surgeries to Outpatient Visits in Children with Inflammatory Bowel Disease: A Population-based Cohort Study from Ontario, Canada. Journal of Crohn's and Colitis, 2021, 15, 1991-2000.	0.6	10
15	Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oil– a prospective 2-year cohort study. Clinical Nutrition, 2021, 40, 4616-4623.	2.3	1
16	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology, 2021, 161, 1043-1051.e4.	0.6	102
17	Multivariable models for advanced colorectal neoplasms in screen-eligible individuals at low-to-moderate risk of colorectal cancer: towards improving colonoscopy prioritization. BMC Gastroenterology, 2021, 21, 383.	0.8	0
18	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut, 2020, 69, 274-282.	6.1	145

#	Article	IF	CITATIONS
19	Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. Journal of the Canadian Association of Gastroenterology, 2020, 3, 169-176.	0.1	2
20	Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease. Digestive Diseases and Sciences, 2020, 65, 1784-1789.	1.1	6
21	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population–Based Analysis. American Journal of Gastroenterology, 2020, 115, 128-137.	0.2	39
22	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. Thrombosis Research, 2020, 194, 26-32.	0.8	8
23	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. Journal of the Canadian Association of Gastroenterology, 2020, 4, 131-136.	0.1	4
24	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis, 2020, 14, 1354-1363.	0.6	38
25	Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 26, 1761-1768.	0.9	35
26	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. BMJ Open, 2020, 10, e041359.	0.8	0
27	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13.	0.9	73
28	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	2.4	32
29	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.1	32
30	Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. BMC Gastroenterology, 2019, 19, 13.	0.8	2
31	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1718-1728.	0.9	31
32	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology, 2019, 2, S17-S33.	0.1	63
33	Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. Clinical Gastroenterology and Hepatology, 2019, 17, 2339-2346.e1.	2.4	24
34	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology, 2019, 156, 1345-1353.e4.	0.6	273
35	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1788-1798.e2.	2.4	23
36	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335.	0.9	7

#	Article	IF	CITATIONS
37	The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2019, 53, 127-133.	1.1	26
38	Temporal trends in postcolonoscopy colorectal cancer rates inÂ50- to 74-year-old persons: a population-based study. Gastrointestinal Endoscopy, 2018, 87, 1324-1334.e4.	0.5	17
39	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	1.5	48
40	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.1	10
41	Variable Endoscopist performance in proximal and distal adenoma detection during colonoscopy: a retrospective cohort study. BMC Gastroenterology, 2018, 18, 73.	0.8	9
42	Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. Endoscopy International Open, 2017, 05, E974-E979.	0.9	15
43	High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study. PLoS ONE, 2017, 12, e0177211.	1.1	8
44	Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 166-167.	2.4	2
45	An Unusual Skin Manifestation in a Patient With UlcerativeÂColitis. Clinical Gastroenterology and Hepatology, 2016, 14, A35-A36.	2.4	3
46	Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2090-2096.	0.9	25